Dr. Thomas Marron, MD PhD
Claim this profileIcahn School of Medicine at Mount Sinai
Area of expertise
Non-Small Cell Lung Cancer
Thomas Marron, MD PhD has run 6 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Solid Tumors
Thomas Marron, MD PhD has run 5 trials for Solid Tumors. Some of their research focus areas include:
Affiliated Hospitals
Icahn School Of Medicine At Mount Sinai
Ichan School Of Medicine At Mount Sinai
Clinical Trials Thomas Marron, MD PhD is currently running
RBS2418
for Cancer
This trial is testing a new drug called RBS2418, alone or with pembrolizumab, for patients with advanced tumors who haven't responded to other treatments. The drug works by boosting the body's natural defenses to better recognize and destroy cancer cells.
Recruiting
1 award
Phase 1
Dupilumab + Cemiplimab
for Early-Stage Lung Cancer
This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study will include participants with a confirmed diagnosis of NSCLC who are deemed to be surgical candidates, or patients who have a smoking history and radiographic findings highly suggestive if a diagnosis of NSCLC who are scheduled to undergo diagnostic biopsy. On Day 1, participants will receive neoadjuvant therapy consisting of 600 mg of dupilumab (2 SC injections of 300 mg) and 350 mg of IV cemiplimab. Participants will undergo standard of care surgery, which will be scheduled within 7 days of Day 15. Participants will be followed up 30 days following administration of dupilumab and cemiplimab for adverse event (AE) and dose limiting toxicity (DLT) monitoring. Participants will be offered adjuvant therapy as per standard of care, outside the context of this clinical treatment, and undergo subsequent standard of care monitoring for recurrence. The study team will monitor the status of the participant through chart review, or by telephone should the patient not continue to follow with a physician at Mount Sinai, for up to 5 years.
Recruiting
1 award
Phase 1 & 2
10 criteria
More about Thomas Marron, MD PhD
Clinical Trial Related
4 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Thomas Marron, MD PhD has experience with
- Pembrolizumab
- Dupilumab
- Cemiplimab
- Nivolumab
- BMS-986253
- Botensilimab
Breakdown of trials Thomas Marron, MD PhD has run
Non-Small Cell Lung Cancer
Solid Tumors
Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Thomas Marron, MD PhD specialize in?
Thomas Marron, MD PhD focuses on Non-Small Cell Lung Cancer and Solid Tumors. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Thomas Marron, MD PhD currently recruiting for clinical trials?
Yes, Thomas Marron, MD PhD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Thomas Marron, MD PhD has studied deeply?
Yes, Thomas Marron, MD PhD has studied treatments such as Pembrolizumab, Dupilumab, Cemiplimab.
What is the best way to schedule an appointment with Thomas Marron, MD PhD?
Apply for one of the trials that Thomas Marron, MD PhD is conducting.
What is the office address of Thomas Marron, MD PhD?
The office of Thomas Marron, MD PhD is located at: Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States. This is the address for their practice at the Icahn School of Medicine at Mount Sinai.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.